Sign inCreate account

Report workspace tools

NCT00321464COMPLETEDanonymous

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab, Zoledronic Acid

Indication / condition

AI-normalized

Bone Metastases

Intervention

Source record

Denosumab, Zoledronic Acid

Source & freshness

Source record

NCT ID

NCT00321464

Original source

ClinicalTrials.gov

Source last updated

Nov 08, 2022

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00321464

Title

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Bone Metastases

Condition normalized

Bone Metastases

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab, Zoledronic Acid

Target normalized

Denosumab, Zoledronic Acid

Interventions

Denosumab, Zoledronic Acid

Public preview

Source record

This clinical trial, sponsored by Amgen and in collaboration with Daiichi Sankyo, aimed to compare the efficacy of Denosumab against Zoledronic Acid in treating bone metastases in patients with advanced breast cancer. The study enrolled 2049 participants and was completed in April 2012.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00321464

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Amgen and in collaboration with Daiichi Sankyo, aimed to compare the efficacy of Denosumab against Zoledronic Acid in treating bone metastases in patients with advanced breast cancer. The study enrolled 2049 participants and was completed in April 2012.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 08, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00321464

Indication

Bone Metastases

Modality

monoclonal antibody

Target

Denosumab, Zoledronic Acid

Intervention

Denosumab, Zoledronic Acid

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.